These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11010595)

  • 1. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer.
    Standaert TA; Vandevanter D; Ramsey BW; Vasiljev M; Nardella P; Gmur D; Bredl C; Murphy A; Montgomery AB
    J Aerosol Med; 2000; 13(2):147-53. PubMed ID: 11010595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled antibiotic therapy in evidence: what delivery device?
    Dennis JH; Pieron CA
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):209-14. PubMed ID: 15463837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal evaluation of compressor/nebulizer performance.
    Awad S; Williams DK; Berlinski A
    Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of aerosol output from various nebulizer/compressor combinations.
    Reisner C; Katial RK; Bartelson BB; Buchmeir A; Rosenwasser LJ; Nelson HS
    Ann Allergy Asthma Immunol; 2001 May; 86(5):566-74. PubMed ID: 11379809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
    Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
    Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.
    de Boer AH; Hagedoorn P; Frijlink HW
    Int J Pharm; 2003 Dec; 268(1-2):59-69. PubMed ID: 14643977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers.
    Coates AL; MacNeish CF; Lands LC; Meisner D; Kelemen S; Vadas EB
    Chest; 1998 Apr; 113(4):951-6. PubMed ID: 9554630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
    Mashat M; Clark BJ; Assi KH; Chrystyn H
    Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crossover Evaluation of Compressors and Nebulizers Typically Used by Cystic Fibrosis Patients.
    Awad SM; Berlinski A
    Respir Care; 2018 Mar; 63(3):294-300. PubMed ID: 29432139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
    Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW
    Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nebulizer configuration on delivery of aerosolized tobramycin.
    O'Riordan TG; Amram JC
    J Aerosol Med; 1997; 10(1):13-23. PubMed ID: 10166359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols.
    Coates AL; MacNeish CF; Meisner D; Kelemen S; Thibert R; MacDonald J; Vadas E
    Chest; 1997 May; 111(5):1206-12. PubMed ID: 9149571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inadequate Functioning of Nebulizer System Compressors Used by Individuals With Cystic Fibrosis.
    Aquino ES; Vergara AA; Filho LVRFS
    Respir Care; 2021 May; 66(5):829-836. PubMed ID: 33688089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of nebulizer type and antibiotic concentration on device performance.
    Weber A; Morlin G; Cohen M; Williams-Warren J; Ramsey B; Smith A
    Pediatr Pulmonol; 1997 Apr; 23(4):249-60. PubMed ID: 9141110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Oct; 54(10):1342-7. PubMed ID: 19796414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
    Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics.
    Standaert TA; Bohn SE; Aitken ML; Ramsey B
    J Aerosol Med; 2001; 14(1):31-42. PubMed ID: 11495483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.